Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Oncologic strategies and options for the management of metastatic thymic carcinoma. | Mediastinum | 2026 | 41982608 | PubTator, text mining | PubMed |
| Targeted Therapies for Each Subtype of Breast Cancer. | MedComm (2020) | 2026 | 41978828 | PubTator, text mining | PubMed |
| Advances in TROP2-targeted antibody-drug conjugates for breast cancer therapy: into the new era. | Cancer Biol Med | 2026 | 41968985 | PubTator, text mining | PubMed |
| Apoptotic cell clearance triggers epithelial fate reprogramming during prostate regression. | Cell Death Dis | 2026 | 41963285 | PubTator, text mining | PubMed |
| Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary. | Gynecol Oncol Rep | 2026 | 41953531 | PubTator, text mining | PubMed |
| ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes. | Clin Cancer Res | 2026 | 41945491 | PubTator, text mining | PubMed |
| The Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas. | Int J Surg Pathol | 2026 | 41940856 | PubTator, text mining | PubMed |
| Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice. | Crit Rev Oncol Hematol | 2026 | 41933852 | PubTator, text mining | PubMed |
| TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. | J Immunother Cancer | 2026 | 41932810 | PubTator, text mining | PubMed |
| Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale. | Drugs | 2026 | 41931218 | PubTator, text mining | PubMed |
| Preclinical activity of SHR-A1921, a novel antibody-drug conjugate targeting trophoblast cell-surface antigen2 (Trop-2) in prostate cancer. | Front Pharmacol | 2026 | 41929251 | PubTator, text mining | PubMed |
Cost-Effectiveness Analysis of Sacituzumab Govitecan Versus Chemotherapy for the Treatment of Metastatic Triple-Negative Breast Cancer With Different Trophoblast Cell-Surface Antigen 2 Expression Levels in Chinese Mainland. | Value Health Reg Issues | 2026 | 41914944 | PubTator, text mining | PubMed |
| Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer. | Front Immunol | 2026 | 41909703 | PubTator, text mining | PubMed |
| Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study. | Ther Adv Med Oncol | 2026 | 41908795 | PubTator, text mining | PubMed |
SNAP-Tag-Based Antibody-Drug Conjugates Targeting Epidermal Growth Factor Receptor 1, Epidermal Growth Factor Receptor 2, Trophoblast Cell-Surface Antigen 2, and Tissue Factor for Ovarian Cancer Treatment. | ACS Omega | 2026 | 41908461 | PubTator, text mining | PubMed |
| Clinical application and optimization strategies for antibody-drug conjugates in solid tumors. | J Int Med Res | 2026 | 41904967 | PubTator, text mining | PubMed |
| Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology. | Pharmaceutics | 2026 | 41900872 | PubTator, text mining | PubMed |
| Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. | Int J Mol Sci | 2026 | 41898574 | PubTator, text mining | PubMed |
| Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer. | Curr Oncol | 2026 | 41892190 | PubTator, text mining | PubMed |
| AdipoR1-AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis. | Cell Death Dis | 2026 | 41888104 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=11